Mankind Pharma Schedules 35th AGM for August 4, 2026
Mankind Pharma Limited's 35th Annual General Meeting is scheduled for August 4, 2026. The meeting will be held via video conference. The Annual Report for FY2025-26 will be shared with members soon.
The scheduling of an AGM is a standard procedural event for a listed company and typically has a minimal impact on the stock price or business operations.
The announcement is a routine corporate event (AGM scheduling) and does not contain any new financial information or strategic changes that would sway the sentiment.
Mankind Pharma Limited has announced that its 35th Annual General Meeting (AGM) will be held on Tuesday, August 4, 2026, at 03:30 p.m. (IST). The meeting will be conducted through Video Conferencing and Other Audio-Visual Means, adhering to the provisions of the Companies Act, 2013, and relevant circulars from the Ministry of Corporate Affairs and SEBI.
The Notice of the AGM, along with the Annual Report for the financial year 2025-26, will be dispatched to the Members in due course, in compliance with the Act, circulars, and Listing Regulations. This information will also be available on the company's website, www.mankindpharma.com.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.